Stock of interest

September 12, 2007

ImClone Systems Inc.

Shares climbed $6.97, or 18.4 percent, to $44.90 after the company said the drug Erbitux improved the survival rate of patients with the most common type of lung cancer in a late-stage study.

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.